A series of statistical tests proved that monitoring lncRNA transcription may have a highly significant potential for the prediction of outcomes in MDS patients, and the only other molecular method able to compete with them is TP53 mutational screening. The gene discussed is TP53; the disease is myelodysplastic syndrome.